Baird Maintains a 'Neutral' on Biogen (BIIB); Hemophilia Update Moderately Incremental; Still All About BG-12

Baird maintains a 'Neutral' on Biogen (NASDAQ: BIIB) price target of $100.00.

Baird analyst says, "No change in outlook after attending yesterday's hemophilia roundtable, where BIIB provided updates on its two late-stage hemophilia programs, rFVIIIFc for hemophilia A and rFIXFc hemophilia B. While market opportunity and early data are promising, these agents' full clinical profiles remain unknown. With the upcoming BG-12 CONFIRM data a much larger catalyst anyway, we still prefer our view from the sidelines."

For more ratings news on Biogen click here and for the rating history of Biogen click here.

Shares of Biogen closed at $91.99 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Wolfe Research Upgrades Biogen (BIIB) to Outperform
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker